MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejcts/ezs589

Медицинская библиотека · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2013

One-year multicentre outcomes of transapical aortic valve implantation using the SAPIEN XT™ valve: the PREVAIL transapical study.

Walther Thomas, Thielmann Matthias, Kempfert Joerg, Schroefel Holger, Wimmer-Greinecker Gerhard, Treede Hendrik, Wahlers Thorsten, Wendler Olaf

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

The study aimed to evaluate 1-year outcomes of the multicentre PREVAIL transapical (TA) study of TA-aortic valve implantation (AVI) in high-risk patients.

METHODS

From September 2009 to August 2010, a total of 150 patients, aged 81.6 ± 5.8 years, 40.7% female, were included at 12 European TA-AVI experienced sites. Patients received 23 (n = 36), 26 (n = 57) and 29 mm (n = 57) second-generation SAPIEN XT™ (Edwards Lifesciences, Irvine, CA, USA) valves. The mean logistic EuroSCORE was 24.3 ± 7.0, and mean Society Thoracic Surgeons score was 7.5 ± 4.4%.

RESULTS

Survival was 91.3% at 30 days and 77.9% at 1 year. Subgroup analysis revealed survivals of 91.7/88.9, 86.0/70.2, 96.55/91.2% for patients receiving 23-, 26- and 29-mm valves at 30 days and at 1 year, respectively. Transthoracic echocardiography revealed preserved left ventricular ejection fraction and low gradients. Aortic incompetence was none in 41/48, trace 30/36, mild 22/12 and moderate in 7/4% at discharge and 1 year. Walking distance increased from 221 (postimplant) to 284 m (at 1 year, P = 0.0004). Three patients required reoperation due to increasing aortic incompetence during follow-up. Causes of mortality at 1 year were cardiac (n = 7), stroke (n = 1) and others (n = 5).

CONCLUSIONS

The European PREVAIL multicentre trial demonstrates good functionality and good outcomes for TA-AVI using the second-generation SAPIEN XT prosthesis and the ASCENDRA-II delivery system. The 29-mm SAPIEN XT valve was successfully introduced and showed excellent results.

Для цитирования: Walther Thomas, Thielmann Matthias, Kempfert Joerg, Schroefel Holger, Wimmer-Greinecker Gerhard, Treede Hendrik, Wahlers Thorsten, Wendler Olaf. One-year multicentre outcomes of transapical aortic valve implantation using the SAPIEN XT™ valve: the PREVAIL transapical study.. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2013. DOI: 10.1093/ejcts/ezs589.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.